American Society of Hirudotherapy

Designing allosteric regulators of thrombin. Exosite 2 features multiple subsites that can be targeted by sulfated small molecules for inducing inhibition

Research article published in Journal of medicinal chemistry (2013)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportSalivary PharmacologyDrug DevelopmentSidhu PS et al. · Journal of medicinal chemistry, 2013

Abstract

We recently designed a group of novel exosite-2-directed sulfated, small, allosteric inhibitors of thrombin. To develop more potent inhibitors, monosulfated benzofuran tri- and tetrameric homologues of the parent designed dimers were synthesized in seven to eight steps and found to exhibit a wide range of potencies. Among these, trimer 9a was found to be nearly 10-fold more potent than the first generation molecules. Michaelis-Menten studies indicated an allosteric mechanism of inhibition. Competitive studies using a hirudin peptide (exosite 1 ligand) and unfractionated heparin, heparin octasaccharide, and γ'-fibrinogen peptide (exosite 2 ligands) demonstrated exosite 2 recognition in a manner different from that of the parent dimers. Alanine scanning mutagenesis of 12 Arg/Lys residues of exosite 2 revealed a defect in 9a potency for Arg233Ala thrombin only confirming the major difference in site of recognition between the two structurally related sulfated benzofurans. The results suggest that multiple avenues are available within exosite 2 for inducing thrombin inhibition.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, N.I.H., Extramural
Indexed MeSH termsAllosteric RegulationBenzofuransBinding SitesBlood CoagulationDimerizationDrug DesignHumansKineticsModels, MolecularProtein ConformationSerine Proteinase InhibitorsSubstrate SpecificitySulfatesThrombin

Summary

Monosulfated benzofuran trimer 9a was found to be roughly 10-fold more potent than prior exosite-2-directed allosteric thrombin inhibitors, with kinetic and mutagenesis studies indicating an exosite 2 binding mode distinct from the parent dimer family.

Why This Matters for Hirudotherapy

This drug-design study synthesized sulfated benzofuran small molecules aimed at thrombin's exosite 2 and identified a trimer (9a) roughly tenfold more potent than earlier dimers, with Michaelis-Menten and alanine-scanning data supporting an allosteric mechanism and a distinct exosite-2 recognition site (a potency defect at Arg233). It connects to hirudotherapy through its experimental use of a hirudin peptide as an exosite-1 ligand in competition studies, illustrating how the leech anticoagulant hirudin serves as a molecular tool and reference point in modern thrombin-inhibitor research. This is in-vitro medicinal chemistry on synthetic compounds, not a study of leech therapy or a clinical investigation, so its relevance is mechanistic and contextual rather than evidence of therapeutic benefit.

Citation

Reference (Vancouver style)

Sidhu PS, Abdel Aziz MH, Sarkar A, Mehta AY, Zhou Q, Desai UR. Designing allosteric regulators of thrombin. Exosite 2 features multiple subsites that can be targeted by sulfated small molecules for inducing inhibition. J Med Chem. 2013;56(12):5059-5070. doi:10.1021/jm400369q. PMID: 23718540

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.